HCW Biologics Regains Ex-vivo Rights to HCW9206 and HCW9201, Keeps 2.2M Shares
HCWB•HCW Biologics regained full ex-vivo commercial rights to its HCW9206 and HCW9201 reagents from Wugen at no additional cost, retaining a 2.2 million-share nonrefundable upfront license fee. Recent data show HCW9206 may lower CAR-T manufacturing costs and enrich long-lived T-memory stem cells, positioning the company for the multi-billion-dollar CAR-T market.
1. Regaining Ex-vivo Rights
HCW Biologics exercised its option to recover worldwide ex-vivo rights to HCW9206 and HCW9201 from Wugen at no additional cost, while retaining the nonrefundable upfront license fee of 2.2 million Wugen shares. This move restores full control over two commercial-ready reagents for cell-based immunotherapies.
2. HCW9206 Scientific Benefits
Recent peer-reviewed data indicate HCW9206’s tri-cytokine fusion scaffold can lower CAR-T manufacturing costs by enhancing production efficiency and enriching long-lived T-memory stem cells, which have been shown to persist longer in vivo and drive complete remissions in blood cancer trials without chemotherapy pre-conditioning.
3. Commercialization and Partnerships
The company plans to partner with established CAR-T and NK-cell therapy developers and manufacturers to commercialize HCW9206 and HCW9201. By leveraging external expertise and infrastructure, HCW Biologics aims to capture a share of the multi-billion-dollar CAR-T market and accelerate reagent adoption.
